Skip to content
Open access

FXYD5 promotes the growth of glioblastoma by targeting the PI3K/AKT/ACSL4 signaling axis

Sep 2026 · Oncology Report · Vol 56 · 0 citations · 54 references
Medicine

TL;DR

Findings revealed that FXYD5 promotes GBM progression via the PI3K/AKT/ACSL4 signaling axis and represents a potential therapeutic target for GBM.

Abstract

Glioblastoma (GBM) is the most malignant primary brain tumor, with limited therapeutic options. Dysregulation of FXYD5 has been reported in multiple malignancies, suggesting FXYD5 as a potential target for precision medicine. In the present study, FXYD5 expression and prognostic significance were analyzed using biological analysis on multiple databases and it was identified that FXYD5 was observably upregulated in GBM and inversely correlated with the prognosis of patients. Functional studies were investigated in LN229 and U251 GBM cell lines through FXYD5 knockdown and overexpression approaches, assessing proliferation (Cell Counting Kit-8), apoptosis (flow cytometry), migration/invasion (Transwell assays) and lipid metabolism (free fatty acids, triglycerides, cholesterol, Nile Red staining). Knockdown of FXYD5 suppressed GBM cell proliferation, migration and invasion, while increasing apoptosis, indicating that FXYD5 may serve as a therapeutic target for GBM. Mechanistic studies examined the PI3K/AKT/long-chain acyl-coenzyme A (CoA) synthase 4 4 (ACSL4) pathway via western blotting and rescue experiments, finding that FXYD5 activated the PI3K/AKT signaling pathway, leading to upregulation of ACSL4 and enhanced lipid metabolism. In vivo, a subcutaneous xenograft mouse model was used to evaluate whether PI3K/AKT inhibition could antagonize FXYD5 overexpression-induced tumor growth and PI3K/AKT inhibition reversed FXYD5 overexpression-induced tumor growth in the subcutaneous mouse model. These findings revealed that FXYD5 promotes GBM progression via the PI3K/AKT/ACSL4 signaling axis and represents a potential therapeutic target for GBM.

Read PDF

Similar papers

Sep 2026

HSP90AA1 inhibits autophagy to promote tumor growth: A novel therapeutic target in endometrial cancer.

HSP90AA1 was significantly overexpressed in tumor tissues, and its high expression correlated with advanced International Federation of Gynecology and Obstetrics stage, lymphovascular space invasion, lymph node metastasis, and higher tumor grade.

L. Xue, Peng-Fei Wang, Chenlingzi Huang et al. · 0 citations
Open access Sep 2026

β3GnT2-mediated N-glycosylation of EGFR and LDLR drives glioblastoma progression and can be targeted by AST-1306

Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by a poor prognosis and limited therapeutic options. In this study, we identify β3GnT2 (β-1,3-N-acetylglucosaminyltransferase 2) as a critical driver of GBM progression and a potential therapeutic target. β3GnT2 is significantly upregulated...

Peng-Fei Shi, Jie Xu, Dandan Zhang et al. · 0 citations
Review Sep 2026

Natural Polyphenols in Glioblastoma: A Multifaceted Approach to Targeting Tumor Progression.

Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with a median survival of less than two years despite surgery, radiotherapy, and temozolomide. Its poor outcome reflects diffuse invasion, cellular heterogeneity, and the activation of overlapping pathways (PI3K/AKT/mTOR, Wnt/β-catenin,...

F. A. Jaber · 0 citations
Open access Aug 2026

34 Therapeutic Targeting of the SLC7A11-GCLM-GPX4 Axis Sensitizes Glioblastoma to Ferroptosis and Associates with Poor Survival

The GPX-4/GCLM axis, which balances redox, is highly expressed and crucial for GBM cell survival and aggressive biological behavior and may be a valuable adjunct to diagnosis, as demonstrated by RSL3, FIN56, and BSO.

M. Behera, S. Purkait, Amit Ghosh et al. · 0 citations
Sep 2026

Defactinib inhibits focal adhesion kinase to attenuate pancreatic cancer growth via PI3K/AKT pathway modulation.

Pancreatic cancer (PC) is a highly lethal malignancy characterized by aggressive progression and limited treatment options. Current standard-of-care treatments only confer marginal survival benefits, highlighting an urgent unmet clinical need to identify novel actionable targets and mechanism-driven therapeutic regimen...

Hui-Deng Long, Hao Wang, Wei Xiang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.